![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 22, 19897-19904, May 31, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the
Received for publication, December 21, 2001, and in revised form, March 4, 2002
Huntingtin-interacting protein 1 (HIP1) and HIP12
are orthologues of Sla2p, a yeast protein with essential functions in
endocytosis and regulation of the actin cytoskeleton. We now report
that HIP1 and HIP12 are major components of the clathrin coat that
interact but differ in their ability to bind clathrin and the clathrin adaptor AP2. HIP1 contains a clathrin-box and AP2 consensus-binding sites that display high affinity binding to the terminal domain of the
clathrin heavy chain and the ear domain of the AP2 Huntington disease, a neurological disorder characterized
by selective loss of striatal and cortical neurons and manifest clinically by chorea and intellectual decline, results from
polyglutamine expansion of huntingtin into the pathologic range of
beyond 35 repeats. In an effort to understand the disease mechanism,
several groups have identified proteins that associate with huntingtin. One such protein, HIP1, was identified in a yeast two-hybrid screen (1,
2). Binding of HIP1 to huntingtin is dramatically reduced following
polyglutamine expansion, strongly implicating this interaction in the
disease process. Subsequent to the identification of HIP1, a highly
related protein (HIP12/HIP1R) was identified based on its homology to
HIP1 (3-5). In contrast to HIP1, HIP12 does not bind directly to
huntingtin (5).
HIP1 and HIP12 are orthologues of yeast Sla2p, a protein that functions
in both endocytosis and regulation of the actin cytoskeleton (6-9).
Each of these proteins contains an ENTH (epsin N-terminal homology)
domain that is thought to be involved in clathrin-mediated endocytosis
through binding to phosphatidylinositol 4,5-bisphosphate-containing membranes (10-13). The central portion of these proteins consists of a
helical domain with a high probability to form coiled-coil interactions, followed by a C-terminal talin-homology domain. The
talin-homology domain has been shown to bind F-actin in Sla2p and HIP12
suggesting a function in linking membrane attachment and
clathrin-coated vesicle
(CCVs)1 formation with actin
dynamics (4, 14).
Recent studies have shown that both HIP1 and HIP12 are enriched on
clathrin-coated pits and CCVs and co-localize with markers of
endocytosis including clathrin, the clathrin adaptor AP2 and Rab5 (4,
15-17). HIP1 binds directly to the terminal domain of the
clathrin heavy chain through a type I clathrin box with the sequence
LMDMD and to the ear domain of the To further characterize the roles of HIP1 and HIP12 in
clathrin-mediated endocytosis, we analyzed and compared the protein interaction and functional properties of these two proteins. Here, we
report that HIP1 strongly associates with CCVs but unlike HIP12, does
not bind directly to F-actin. In contrast, HIP12 does not demonstrate
high affinity binding to clathrin and AP2 as seen for HIP1. However,
HIP1 and HIP12 both bind directly to the clathrin light chain through
their central helical domain that interestingly, stimulates clathrin
assembly. These results suggest related but distinct functions for HIP1
and HIP12 in clathrin-mediated endocytosis and identify a novel
interaction with clathrin light chain that appears to contribute to
clathrin assembly.
Antibodies and Reagents--
Rabbit polyclonal antibodies
against HIP1 (HIP1FP) and HIP12 (HIP12FP) and a mouse monoclonal
antibody against HIP1 (mAb HIP no. 9) were previously described (5,
15). Monoclonal antibodies against the clathrin heavy chain and
DNA Constructs and Recombinant Proteins--
Mammalian
expression constructs encoding full-length HIP1 and HIP12 and the talin
homology domain of HIP1, each with a FLAG epitope tag at the C
terminus, were previously described (5, 15). A construct encoding human
full-length HIP12 with a C-terminal HA epitope tag was generated
by insertion of a cDNA sequence, 5'-GGAGGTGGATATCCCTATGATGTCCCCGATTATGCC, encoding a linker of 3 glycines followed by the HA tag. The integrity of the HA-tagged HIP12
construct was verified by DNA sequencing. Bacterial fusion proteins
encoding His6-tagged terminal domain of the clathrin heavy
chain and the amino acids 276-335 of HIP1 fused to GST
(GST-HIP1-(276-335)) were previously described (15). A
His6-tagged construct encoding full-length clathrin light
chain b was generated by subcloning the GFP-clathrin light chain b
cDNA (kindly provided by Dr. Juan Bonifacino) into the pTrcHisB
bacterial expression vector (Qiagen). The following HIP1 and HIP12 GST
fusion proteins were created by PCR amplification from either
full-length HIP1 or HIP12 cDNAs with subsequent cloning into
pGEX-2T or pGEX-4T vectors (Amersham Biosciences):
GST-HIP12-(302-348), GST-HIP1-(336-610), GST-HIP12-(349-644), GST-HIP1-(731-1003) (GST-HIP1-talin), and GST-HIP12-(765-1068) (GST-HIP12-talin).
Pull-down Assays--
Rat brains were homogenized in buffer A
(10 mM HEPES-OH, pH 7.4, 0.83 mM benzamidine,
0.23 mM phenylmethylsulfonyl fluoride, 0.5 µg/ml
aprotinin, and 0.5 µg/ml leupeptin) and the homogenates were
centrifuged at 205,000 × gmax for 30 min
at 4 °C. The supernatant (cytosolic extract) was collected and
Triton X-100 was added to 1% final concentration. Aliquots of the
extract (2 mg) were incubated overnight at 4 °C with GST fusion
proteins pre-coupled to glutathione-Sepharose beads. After incubation,
samples were washed three times in buffer A containing 1% Triton
X-100. For binding experiments, purified His6-tagged
clathrin terminal domain or clathrin light chain b fusion proteins (15 µg) in buffer A were incubated overnight at 4 °C with various GST
fusion proteins pre-coupled to glutathione-Sepharose beads. After
incubation, samples were washed three times in buffer A. In all cases,
proteins specifically bound to the beads were eluted with gel sample
buffer and analyzed by SDS-PAGE and Western blot.
For pull-downs from transfected cells, HeLa cells were grown on
10-cm2 dishes and transfected with 6 µg of HIP1 or HIP12
cDNA using FuGENE (Roche Molecular Biochemicals). Twenty-four h
post-transfection, cells were washed twice with ice-cold
phosphate-buffered saline (PBS) and lysed in buffer A (containing 1%
Triton X-100 and 10 µM Pefa (Roche Molecular
Biochemicals). Samples were incubated overnight at 4 °C with GST
fusion proteins pre-coupled to glutathione-Sepharose beads. After
incubation, samples were washed three times in buffer A containing 1%
Triton X-100 and 10 µM Pefa. Bound proteins were analyzed
by SDS-PAGE and transferred to nitrocellulose for Western blot analysis.
Immunoprecipitation Assays--
HEK-293T cells were grown on
10-cm2 plates and transfected with 4 µg of HIP12 cDNA
by CaPO Immunofluorescence--
Cells were plated onto gelatinized glass
slides in 6-well tissue culture plates and transfected with 1 µg of
HIP1 or HIP12 cDNA. Twenty-four h post-transfection, the cells were
washed in PBS, fixed in PBS containing 4% paraformaldehyde for 15 min
at room temperature, and permeabilized in PBS containing 0.3% Triton X-100 and 1% paraformaldehyde for 5 min. The cells were then incubated in PBS containing 3% normal goat serum for 30 min to block nonspecific binding. Depending on the experiment, the cells were then incubated with monoclonal antibodies against the FLAG or HA epitopes for 1 h
at room temperature or overnight at 4 °C with a polyclonal antibody
against HIP1, followed by a 1-h incubation at room temperature with
appropriate secondary antibodies in PBS containing 2% normal goat
serum. Staining of the actin cytoskeleton was achieved by incubation
with Texas Red-phalloidin. Cells were then extensively washed in PBS,
mounted, and observed on a BioRad Radiance Plus confocal microscope
(BioRad, Hercules, CA) using Laser Sharp software (BioRad).
Actin-binding Assays--
Purified human non-muscle monomeric
actin (Cytoskeleton Inc.) was polymerized as described previously (4)
and incubated with purified GST-HIP1-talin and GST-HIP12-talin (20 µg
each) for 1 h at room temperature in a final volume of 50 µl.
The samples were then centrifuged for 30 min at 362,000 × gmax. Protein components of the pellets and
supernatants were analyzed by SDS-PAGE followed by Coomassie Blue
staining. Gels were scanned on a ScanJet 6300 (Hewlett Packard) and
protein amounts were determined using Quantity One (Bio-Rad) software.
Statistical analysis was done by the Student's t test.
Clathrin Purification and Clathrin Assembly Assays--
CCVs
were purified from adult rat brains as described (18). To purify
clathrin, coats were stripped from the vesicles by incubation in buffer
B (0.5 M Tris, pH 7.0, 2 mM EDTA, 0.83 mM benzamidine, 0.23 mM phenylmethylsulfonyl fluoride, 0.5 µg/ml aprotinin, and 0.5 µg/ml leupeptin) for 15 min on ice. The
samples were then centrifuged for 15 min at 245,000 × gmax with the purified coat fraction remaining
in the supernatant. The stripping and centrifugation steps were
repeated a second time and the supernatants were pooled. The pooled
supernatants were loaded onto a continuous 5-20% sucrose gradient
made in buffer B and then centrifuged for 3.5 h at 195,000 × gmax in a Sorvall Step Saver vertical rotor. Fractions of 2 ml were collected and analyzed by SDS-PAGE and Coomassie
Blue staining. Peak clathrin fractions were pooled and dialyzed
overnight in clathrin assembly buffer (10 mM Tris-Cl, pH
8.5) and subsequently used for clathrin assembly assays.
Clathrin assembly assays were performed with 0.5 µM
purified clathrin and different concentrations (0.12-2
µM) of fusion proteins in a final volume of 90 µl of
clathrin assembly buffer. Assembly was initiated at 4 °C by addition
of 10 µl of 1 M MES, pH 6.7. The mixture was kept on ice
for 45 min and then centrifuged at 400,000 × gmax for 6 min. The supernatant (80 µl) was
loaded on a SDS-PAGE and the clathrin assembly was quantified by
Coomassie Blue staining.
HIP1 and HIP12 Are Abundant Coat Proteins of CCVs of Adult and
Embryonic Rat Brains--
Both HIP1 and HIP12 have been implicated in
clathrin-mediated endocytosis (4, 15-17, 19). To further characterize
the endocytic functions of these proteins, we sought to directly
compare their biochemical and functional properties. Both HIP1 and
HIP12 are predominantly expressed in brain (1, 2). Within brain, however, the two proteins demonstrate distinct developmental expression profiles (Fig. 1A).
Specifically, HIP1 is most highly expressed during early development,
with the highest detectable levels at embryonic day 13 (E13) and E16,
whereas HIP12 expression is only weakly detectable at E13 through E18
but increases in postnatal day 2 rats with high levels of expression in
adult brain (Fig. 1A). Interestingly, both HIP1 and HIP12
are highly enriched on the coats that are stripped from purified CCVs
prepared from E18 brains (data not shown) and adult brains (Fig.
1B). HIP1 and HIP12 show a comparable enrichment in the CCV
fractions to both each other and to the coat proteins clathrin and AP2
(data not shown and Fig. 1B). Moreover, both proteins appear
to be major components of the clathrin coats (Fig. 1C). To
make this determination, coat proteins stripped from adult or E18 CCVs
where fractionated on linear 5-20% sucrose gradients, which readily
separated HIP1 and HIP12 from the large subunits of the adpatin
complexes (Fig. 1C). Coomassie Blue staining of the
fractions revealed that HIP1 and HIP12 where present on E18 or adult
rat brain CCVs, respectively, at near stoichiometric levels with
adaptin subunits (Fig. 1C).
HIP1 and HIP12 Co-localize and Interact--
Earlier work in our
laboratory has shown that HIP1 and HIP12 interact in the yeast
two-hybrid system (5). To confirm this interaction,
co-immunoprecipitation studies were performed in HEK-293T cells.
Immunoprecipitation of endogenous HIP1 with a monoclonal antibody led
to co-immunoprecipitation of endogenous HIP12 whereas no precipitation
of HIP12 was seen in the absence of HIP1 antibody (Fig.
2A). Transfection of the cells
with HIP12 cDNA led to a significantly greater immunoprecipitation
of HIP12 by endogenous HIP1 (Fig. 2A). We next analyzed the
intracellular localization of HIP1 and HIP12 in neuronal NT2 cells
following transfection of HA-tagged HIP12. Confocal microscopy analysis of the expression of HIP12-HA shows punctate staining throughout the
cell and extensive co-localization with endogenous HIP1 (Fig. 2B). These punctae correspond predominantly to
clathrin-coated pits and CCVs as previously described (4, 15).
To determine the regions of HIP1 and HIP12 that mediate their
interaction, pull-down experiments were performed. Previous studies
have shown that a small fragment of HIP12 encompassing the helical
domain interacts with HIP1 in the yeast two-hybrid system (5).
Therefore, we analyzed whether HIP1 and HIP12 interact through their
helical domains. In fact, the helical domains of both HIP1 and HIP12
are sufficient to specifically pull-down HIP12 and HIP1, respectively
(Fig. 2C). These studies suggest that the HIP1-HIP12
interaction could affect specific functions of each protein.
HIP1 and HIP12 Display Differential Binding to Clathrin and
AP2--
Between its ENTH and helical domains, HIP1 contains a
clathrin-box consensus sequence, LMDMD, which binds to the terminal domain of the clathrin heavy chain (15). This sequence is found in
close association with the sequences FDNKF, FDDIF, FGSSF, and DPF,
which match consensus sequences for binding to AP2 (17). Upon sequence
alignment, the LMDMD motif in HIP1 aligns with the sequence LIEIS in
HIP12 (Fig. 3A). The LIEIS
sequence resembles a clathrin-box motif similar to that found in the
clathrin-binding proteins ACK1 and ACK2 (20, 21). In contrast, the DPF
motif is absent from HIP12 and the FDNKF, FDDIF, and FGSSF sequences, which match the consensus FX(N/D/S)X(F/L) (17),
are not conserved (Fig. 3A). We thus designed a HIP1-GST
fusion protein, GST-HIP1-(276-335), encompassing these sites (Fig.
3B) and tested for its ability to bind clathrin and AP2 in
comparison with a GST fusion protein encoding the corresponding region
of HIP12, GST-HIP12-(302-348). As previously demonstrated (15),
GST-HIP1-(276-335) binds strongly to clathrin (Fig. 3C, top
panel). In contrast, GST-HIP12-(302-348) demonstrates much weaker
clathrin binding (Fig. 3C, top panel). In both cases, the
binding is mediated through the terminal domain of the clathrin heavy
chain (15) (data not shown). Moreover, GST-HIP1-(276-335) binds
strongly to AP2 whereas no binding of GST-HIP12-(302-348) to AP2 was
detected (Fig. 3C, bottom panel).
In Contrast to HIP12, HIP1 Does Not Bind Actin--
HIP12 binds
actin through its talin-homology domain (4). To determine whether the
talin homology domain of HIP1 also mediates actin binding, a
GST-HIP1-talin homology domain fusion protein was analyzed for
co-sedimentation with F-actin. As a control, the talin homology domain
of HIP12 was expressed as a GST fusion protein and analyzed in
parallel. Surprisingly, in contrast to HIP12, HIP1 bind only very
weakly to actin in vitro (Fig.
4A). Specifically, in the
presence of 5 µM F-actin, 87.6% ± 6.0 (mean ± S.E., n = 3) of GST-HIP12-talin homology domain was
bound to F-actin. In contrast, only 19.3% ± 3.7 (mean ± S.E.,
n = 3) of the GST-HIP1-talin homology domain was bound
to the same amount of polymerized actin (Fig. 4B). A number
of different parameters such as pH and ion concentrations were tested
for their potential effect on the binding of HIP1-talin to actin.
However, none of these alterations allowed for increased binding (data
not shown). Consistent with this observation is the lack of
co-localization between the HIP1-talin homology domain and the cortical
actin cytoskeleton following overexpression of HIP1-talin in cultured cells (Fig. 4C). This is in contrast to the observation that
the talin homology domain of HIP12 shows enrichment along cortical actin filaments (4).
HIP1 and HIP12 Contain a Second Clathrin-binding Site in Their
Helical Domain--
We previously demonstrated that
GST-HIP1-(219-616), encompassing the clathrin box motif and the
helical domain, demonstrated stronger binding to clathrin than
GST-HIP1-(276-335) alone, encompassing only the clathrin box consensus
site (15). This observation led us to suggest the presence of a second
clathrin-binding site in the helical domain of HIP1 (15). Moreover, the
helical domains of HIP1 and HIP12 were recently reported to mediate
binding to clathrin (16, 19). We thus designed fusion proteins
encompassing the helical domains of HIP1, GST-HIP1-(336-610) and
HIP12, GST-HIP12-(349-644) (Fig.
5A) and tested their ability
to bind clathrin and AP2. Both fusion proteins show specific binding to
clathrin from brain extracts (Fig. 5B, top panel) but not to
AP2 (Fig. 5B, bottom panel).
HIP1 and HIP12 Promote Clathrin Assembly through Their Helical
Domains--
Full-length HIP12 stimulates clathrin assembly (19).
Moreover, both HIP1 and HIP12 contain a DLL motif in their helical domains that contributes to the clathrin assembly activity of other
clathrin adaptor proteins (22). We thus tested the ability of both of
the helical domains to promote clathrin assembly in vitro.
Interestingly, both GST-HIP1-(336-610) and GST-HIP12-(348-644) fusion
proteins stimulated clathrin assembly in a dose-dependent manner with full activity detected in the presence of 0.5 µM fusion protein (Fig. 6).
In contrast, GST alone did not stimulate clathrin assembly (Fig. 6).
These results demonstrate that like HIP12 (19), HIP1 stimulates
clathrin assembly, and that for both proteins, assembly activity is
localized to their helical domains, which demonstrate weak clathrin
binding.
HIP1 and HIP12 Bind Directly to Clathrin Light
Chain--
Inspection of the helical domains of HIP1 and HIP12 failed
to reveal any type I or type II clathrin box sequences (23) that could
mediate interactions with the terminal domain of the clathrin heavy
chain. This suggested the possibility of a novel form of clathrin
interaction mediated by the helical domains. To explore this further,
we performed additional binding assays with GST-HIP1-(336-610) and
GST-HIP12-(348-644). Consistent with the lack of consensus clathrin
terminal domain-binding sites, neither helical domain fusion protein
bound to purified His6-tagged clathrin terminal domain
(Fig. 7A, bottom
panel), whereas the same fusion proteins bound to clathrin heavy
chain from brain extracts (Fig. 7A, top panel). Clathrin
exists in the cytosol of cells as a triskelia, in which three molecules
of clathrin heavy chain are associated with three molecules of clathrin
light chain (24). Thus, it is possible that the helical domain fusion
proteins bind to clathrin light chain leading to an indirect
interaction with the heavy chain. This idea is supported by the recent
observation that addition of light chains to truncated clathrin cages
restores their ability to bind HIP12 (19). To directly test if the
helical domains of HIP1 and HIP12 bind to clathrin light chain, we
generated a His6-tagged fusion protein encoding full-length
clathrin light chain b. Interestingly, this purified fusion protein
bound strongly to the HIP1 and HIP12 helical domain GST fusion proteins
(Fig. 7B). Taken together, these studies demonstrate that
the helical domains of HIP1 and HIP12 do not interact with the clathrin
heavy chain via its terminal domain, although we cannot rule out the possibility that they could interact with the proximal or distal legs
of the heavy chain. In contrast, HIP1 and HIP12 bind directly to the
clathrin light chain through the helical domains, which also stimulate
clathrin assembly.
Many proteins involved in clathrin-mediated endocytosis harbor a
facet of protein interaction modules that enable them to function in
the recruitment of clathrin triskelia to sites of endocytosis and in
the subsequent formation of CCVs, shedding of coat proteins, and
intracellular transport of the uncoated vesicle (25, 26). In the
present work, we show that two family members, HIP1 and HIP12, are
major components of CCVs. As such, they are comparable in their
enrichment on purified vesicles to the coat proteins Several endocytic accessory proteins that participate in the formation
of clathrin-coated pits and CCVs contain a tandem arrangement of high
affinity clathrin and AP2 consensus-binding sites including amphiphysin
I (29), epsin (30), and arrestins (31). This tandem arrangement of
consensus sites is also found in HIP1 but is not conserved in the HIP1
family member HIP12. HIP12 does not contain the DPF/W or
FX(N/D/S)X(F/L) consensus AP2-binding sites (17, 32, 33) and
correspondingly does not show binding to AP2. Moreover, the clathrin
box motif that is present in HIP12 binds clathrin with rather low
affinity. Since the tandem arrangement of clathrin- and AP2-binding
sites is thought to stabilize clathrin/adaptor interactions (30), HIP12
probably contributes less to the stabilization of this protein complex.
As such, HIP12 is comparable with amphiphysin II that interacts with
clathrin through type I and type II clathrin box sequences but does not
bind to AP2 (34, 35).
The formation of clathrin-coated pits does not occur randomly. Instead,
defined sites of endocytosis exist that are demarcated by AP2 (36) with
extended areas of the membrane not being involved in coated pit
formation (37). It has been proposed that the underlying membrane
cytoskeleton contains coated pit-nucleation sites and that actin may be
involved in the spatial organization of endocytic components at the
membrane (37, 38). Interestingly, both HIP1 and HIP12 contain an ENTH
domain, a PtdIns(4,5)P2-binding motif that is found in
several other coat and accessory proteins including AP180 and epsins
(11, 12). Recent studies have demonstrated that
PtdIns(4,5)P2 is localized predominantly on the plasma
membrane of quiescent neurons but that its levels are increased on
endocytic membranes following stimulation of endocytic activity (39). In addition to potential PtdIns(4,5)P2 binding, HIP1 and
HIP12 contain a talin homology domain that in HIP12 binds directly to actin (4). Thus, it is intriguing to speculate that HIP1 and HIP12 may
play a role in the coordination of clathrin, actin, and
PtdIns(4,5)P2 functions at the plasma membrane to demarcate sites of clathrin assembly. Surprisingly, however, HIP1 does not bind
to actin. This appears to result from the observation that a helical
segment at the N terminus of the talin homology domain of HIP1 can
disrupt actin binding through an intrasteric interaction (40).
Nevertheless, heterodimerization of HIP1 and HIP12 may be a mechanism
that allows HIP1 to indirectly bind to F-actin and that also allows AP2
to be recruited to clathrin nucleation sites defined by the HIP
proteins at the plasma membrane.
Consistent with a role for the HIP1-HIP12 complex in defining endocytic
active zones, HIP12 has been demonstrated to stimulate clathrin
assembly (19). Here, we have determined that HIP1 also functions in
clathrin assembly and that for both proteins assembly activity is
localized to the helical domain. GST fusion proteins encoding the
helical domains of HIP1 and HIP12 are also able to affinity purify
clathrin triskelia from brain extracts. Interestingly, the helical
domains do not bind to the terminal domain of the clathrin heavy chain
but do bind directly to the clathrin light chain, consistent with
recent results demonstrating that light chains are necessary for HIP12
binding to clathrin hub domains (19). Clathrin triskelia, composed of
three heavy chains, each with a bound light chain, assemble into a
polyhedral lattice at physiological pH only in the presence of assembly
proteins such as AP2 or AP180. Interestingly, it has been proposed that
the light chains interact with the distal legs of the clathrin heavy chains to prevent clathrin assembly (41). Specifically, the recombinant
hub fragments of the clathrin heavy chains assemble in the absence of
light chains at physiological pH whereas addition of purified light
chains blocks the assembly reaction (41). Moreover,
Src-dependent phosphorylation of the clathrin heavy chain
at tyrosine 1477, a site that appears to be involved in binding to
light chain, stimulates clathrin assembly, possibly by releasing the
inhibitory effect of the light chain (42). Thus, HIP1 and HIP12 may
stimulate clathrin assembly by interacting with the clathrin light
chain and through an unknown mechanism release light chain-mediated
inhibition allowing the heavy chains to interact and assemble (41).
This model is consistent with the observation that overexpression of
HIP12 in cultured cells causes a mislocalization of the light chains
without a major effect on the distribution of the heavy chains (19).
HIP1 and HIP12 are the first assembly proteins demonstrated to interact
directly with clathrin light chain and this interaction appears to
reveal a novel mechanism involved in the regulation of clathrin assembly.
Growing evidence suggests a role for the disease-associated protein
huntingtin in clathrin-mediated endocytosis and intracellular vesicle
transport. For example, huntingtin associates with the We thank Dr. Juan Bonifacino for the gift of
GFP-clathrin light chain b. We also thank Heather Heine for excellent
technical assistance and Olivier Guillemin for help with graphics.
*
This work was supported in part by the Canadian Genetics
Disease Network (CDGN), Canadian Institutes of Health Research (CIHR) Grants MT-9133 (to M. R. H.) and MT-15396 (to P. S. M.), and Merck-Frosst Canada (to M. R. H. and M. M.).The costs of publication of this article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Both authors contributed equally to this work.
¶
Supported by a postdoctoral fellowship from the Canadian
Institutes of Health Research.
**
Canadian Institutes of Health Research Investigator and a McGill
University William Dawson Scholar. To whom correspondence should be
addressed: Dept. of Neurology and Neurosurgery, Montreal Neurological
Institute, McGill University, 3801 rue University, Montreal, QC, H3A
2B4, Canada. Tel.: 514-398-7355; Fax: 514-398-8106; E-mail:
peter.mcpherson@mcgill.ca.
Published, JBC Papers in Press, March 11, 2002, DOI 10.1074/jbc.M112310200
The abbreviations used are:
CCVs, clathrin
coated vesicles;
AP2, adaptor protein 2;
CHC, clathrin heavy chain;
ENTH, Epsin N-terminal homology;
GST, glutathione
S-transferase;
HIP1, huntingtin interacting protein 1;
PBS, phosphate-buffered saline;
PCR, polymerase chain reaction;
PtdIns(4, 5)P2, phosphatidylinositol (4,5)-bisphosphate;
HA, hemagglutinin;
MES, 4-morpholineethanesulfonic acid.
HIP1 and HIP12 Display Differential Binding to F-actin, AP2,
and Clathrin
IDENTIFICATION OF A NOVEL INTERACTION WITH CLATHRIN LIGHT
CHAIN*
§¶,
,
,
,
,
,
, and
**
Department of Neurology and Neurosurgery,
Montreal Neurological Institute, McGill University, Montreal,
Quebec H3A 2B4, Canada and the
Centre for Molecular
Medicine and Therapeutics, Department of Medical Genetics
University of British Columbia, Vancouver,
British Columbia V5Z 4H4, Canada
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
subunit, respectively. These consensus sites are poorly conserved in HIP12 and
correspondingly, HIP12 does not bind to AP2 nor does it demonstrate high affinity clathrin binding. Moreover, HIP12 co-sediments with F-actin in contrast to HIP1, which exhibits no interaction with actin
in vitro. Despite these differences, both proteins
efficiently stimulate clathrin assembly through their central helical
domain. Interestingly, in both HIP1 and HIP12, this domain binds
directly to the clathrin light chain. Our data suggest that HIP1 and
HIP12 play related yet distinct functional roles in
clathrin-mediated endocytosis.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
subunit of AP2 (15-17).
Moreover, a fragment of HIP1 containing the clathrin and AP2-binding
sites blocks clathrin-mediated endocytosis (15, 17).
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-adaptin were purchased from Transduction Laboratories. Monoclonal
antibody against the clathrin light chain was purchased from Santa
Cruz. Monoclonal antibodies against the FLAG, HA, and His6
epitopes were purchased from Sigma, Roche Molecular Biochemicals, and
Qiagen, respectively.

![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (41K):
[in a new window]
Fig. 1.
HIP1 and HIP12 are coat proteins of CCVs and
display distinct developmental expression profiles. A,
post-nuclear supernatants (100 µg) from brain extracts of various rat
developmental stages were analyzed by Western blot with anti-HIP1 or
anti-HIP12 antibodies as indicated. E, embryonic day;
P, post-natal day; A, adult.
B, purified CCVs were obtained by subcellular
fractionation of adult rat brain homogenates. Aliquots (100 µg) of
the various fractions were analyzed by Western blot with antibodies
against clathrin heavy chain (CHC), the
-adaptin subunit
of AP2 (AP2), HIP1 and HIP12, as indicated. H,
homogenate; P, pellet; S, supernatant;
SGp, sucrose gradient pellet; SGs,
sucrose gradient supernatant; C, coats;
V, vesicles. The coats and vesicles correspond to the
supernatant and pellet fractions, respectively, following incubation of
the purified CCVs with 0.5 M Tris, pH 9.0. C, purified CCVs from adult and E18 brains were
stripped of their coats in 0.5 M Tris, pH 7.0, 2 mM EDTA. Aliquots of the coat fractions were analyzed on
SDS-PAGE and Coomassie Blue staining (panels at
left). The coat proteins were then fractionated on
continuous 5-20% sucrose gradients. The gradients were collected in
20 equal fractions and aliquots from fractions 7-18 were analyzed by
SDS-PAGE with Coomassie Blue staining (Coomassie). The
migration of HIP1 and HIP12 was determined by Western blot as
indicated. The bracket on the E18 gradient demonstrates the
migratory positions of the large subunits of the adaptins, whereas the
arrow indicates the migratory position of HIP1.

View larger version (34K):
[in a new window]
Fig. 2.
HIP1 and HIP12 interact via their helical
domains. A, HEK 293T cells were transfected with
full-length HIP12 cDNA (HIP12) or were left untransfected (
).
Cell lysates were prepared and immunoprecipitations were carried out in
the presence or absence (
AB) of mouse mAb HIP1#9. Cell
lysate (SM) and immunoprecipitated protein (IP)
were analyzed by SDS-PAGE and Western blot with anti-HIP12FP antibody.
B, co-localization of transfected HIP12-HA
(red) and endogenous HIP1 (green) was analyzed in
neuronal NT2 cells. Overlays of the images are shown in the
panel on the right (overlay).
Scale bar = 10 µM. C,
HeLa cells were transfected with either HIP1 or HIP12 full-length
cDNA as indicated. Cell extracts were prepared and tested for
binding to GST alone or various HIP12 and HIP1 GST fusion proteins.
Equal volumes of unbound and bound proteins were analyzed by SDS-PAGE
and Western blot with anti-HIP1 and anti-HIP12 antibodies as
indicated.

View larger version (31K):
[in a new window]
Fig. 3.
HIP1 and HIP12 display differential binding
to clathrin and AP2. A, sequence alignment of a
region of HIP1 and HIP12 demonstrating consensus clathrin and
AP2-binding sites. B, schematic representation of
various GST fusion proteins used for the binding assays.
C, soluble proteins from brain extracts were affinity
purified with equal amounts of HIP1 or HIP12-GST fusion proteins bound
to glutathione-Sepharose beads. Proteins specifically bound to the
beads were analyzed by Western blot with antibodies against CHC or the
-adaptin subunit of AP2 (AP2) as indicated.

View larger version (29K):
[in a new window]
Fig. 4.
HIP1 does not bind actin in contrast to
HIP12. A, binding of the HIP1-talin homology
domain expressed as a GST fusion protein (HIP1-talin) to
filamentous actin was analyzed by cosedimentation in the presence of
various concentrations of assembled actin (0-10 µM).
Binding of the HIP12-talin homology domain GST fusion protein
(HIP12-talin) was used as positive control. The
arrows indicate HIP1 or HIP12 fusion proteins in the
supernatant (S) and pellet (P) fractions.
B, the percentage of GST-HIP1-talin bound to actin is
shown as mean ± S.E. of three independent experiments.
C, HeLa cells expressing a FLAG-tagged construct
encoding the HIP1-talin homology domain (HIP1-talin-Flag)
were immunostained with an anti-FLAG antibody shown in green
and with Texas Red-phalloidin shown in red to reveal
F-actin. Overlays of the confocal images are shown in the
right. Scale bar = 10 µM.

View larger version (21K):
[in a new window]
Fig. 5.
The helical domains of HIP1 and HIP12 bind to
clathrin but not AP2. A, schematic representation of
various GST fusion proteins used for the binding assays. B,
soluble proteins from brain extracts were affinity purified with equal
amounts of HIP1 or HIP12 GST fusion proteins bound to
glutathione-Sepharose beads. Proteins specifically bound to the beads
were analyzed by Western blot with antibodies against CHC or the
-adaptin subunit of AP2 (AP2) as indicated.

View larger version (42K):
[in a new window]
Fig. 6.
HIP1 and HIP12 promote clathrin assembly
through their helical domains. An aliquot of the purified clathrin
used as a starting material (SM) for the clathrin assembly
assays was resolved on SDS-PAGE and stained with Coomassie Blue.
Clathrin assembly assays were performed with increasing amounts of
fusion proteins GST, GST-HIP1-(336-610), and GST-HIP12-(348-644) as
indicated. The GST fusion proteins and the clathrin remaining in the
supernatant after high-speed centrifugation following initiation of
clathrin assembly were analyzed by SDS-PAGE and Coomassie Blue
staining.

View larger version (43K):
[in a new window]
Fig. 7.
HIP1 and HIP12 bind directly to the clathrin
light chain through their helical domains. A,
soluble proteins from brain extracts or purified
His6-tagged clathrin terminal domain (TD) fusion
protein were affinity purified with equal amounts of HIP1 or HIP12 GST
fusion proteins bound to glutathione-Sepharose beads. Proteins
specifically bound to the beads were analyzed by Western blots with
antibodies against CHC or the His epitope (tetra-HIS) as indicated.
B, purified His6-tagged clathrin light chain b
(LCb) fusion protein was affinity purified with equal
amounts of HIP1 or HIP12 GST fusion proteins bound to
glutathione-Sepharose beads. Proteins specifically bound to the beads
were analyzed by Western blot with the anti-His epitope antibody
(tetra-HIS).
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-adaptin,
clathrin, and AP180. In contrast, accessory proteins of
clathrin-mediated endocytosis such as dynamin, synaptojanin,
amphiphysin I and II, epsin, endophilin, and Eps15 are far less
enriched on CCVs (27). Moreover, HIP1 and HIP12 are present on CCVs at
near stoichiometric levels with the adaptor proteins. Finally, both
proteins can be stripped from purified vesicles by treatment with Tris
buffer, which is well established to remove coat components from
vesicles (28). Thus, HIP1 and HIP12 should be considered as novel
members of the clathrin coat.
-adaptin C
subunit of the AP2 complex (43) and with endophilin A3 (44) and it
associates with vesicles and microtubules (44-47). The interaction of
huntingtin with AP2 and endophilin suggests that huntingtin
participates in the complex network of interactions regulating
clathrin-mediated endocytosis and vesicle recycling. Huntingtin has
been localized to endosomal and lysosomal membranes (48) and it is
present but not enriched on purified CCVs (46) (data not shown).
Intriguingly, the interaction of HIP1 with huntingtin is directly
modulated by polyglutamine expansion in huntingtin, suggesting that
disturbances in protein interaction and subsequent alterations in
clathrin-mediated endocytosis could contribute to the pathogenesis of
Huntington disease.
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Kalchman, M. A.,
Koide, H. B.,
McCutcheon, K.,
Graham, R. K.,
Nichol, K.,
Nishiyama, K.,
Kazemi-Esfarjani, P.,
Lynn, F. C.,
Wellington, C.,
Metzler, M.,
Goldberg, Y. P.,
Kanazawa, I.,
Gietz, R. D.,
and Hayden, M. R.
(1997)
Nat. Genet.
16,
44-53[CrossRef][Medline]
[Order article via Infotrieve]
2.
Wanker, E. E.,
Rovira, C.,
Scherzinger, E.,
Hasenbank, R.,
Walter, S.,
Tait, D.,
Colicelli, J.,
and Lehrach, H.
(1997)
Hum. Mol. Genet.
6,
487-495 3.
Seki, N.,
Muramatsu, M.,
Sugano, S.,
Suzuki, Y.,
Nakagawara, A.,
Ohhira, M.,
Hayashi, A.,
Hori, T.,
and Saito, T.
(1998)
J. Hum. Genet.
43,
268-271[CrossRef][Medline]
[Order article via Infotrieve]
4.
Engqvist-Goldstein, A. E.,
Kessels, M. M.,
Chopra, V. S.,
Hayden, M. R.,
and Drubin, D. G.
(1999)
J. Cell Biol.
147,
1503-1518 5.
Chopra, V. S.,
Metzler, M.,
Rasper, D. M.,
Engqvist-Goldstein, A. E.,
Singaraja, R.,
Gan, L.,
Fichter, K. M.,
McCutcheon, K.,
Drubin, D.,
Nicholson, D. W.,
and Hayden, M. R.
(2000)
Mamm. Genome
11,
1006-1015[CrossRef][Medline]
[Order article via Infotrieve]
6.
Holtzman, D. A.,
Yang, S.,
and Drubin, D. G.
(1993)
J. Cell Biol.
122,
635-644 7.
Raths, S.,
Rohrer, J.,
Crausaz, F.,
and Riezman, H.
(1993)
J. Cell Biol.
120,
55-65 8.
Wesp, A.,
Hicke, L.,
Palecek, J.,
Lombardi, R.,
Aust, T.,
Munn, A. L.,
and Riezman, H.
(1997)
Mol. Biol. Cell
8,
2291-2306 9.
Yang, S.,
Cope, M. J.,
and Drubin, D. G.
(1999)
Mol. Biol. Cell
10,
2265-2283 10.
Kay, B. K.,
Yamabhai, M.,
Wendland, B.,
and Emr, S. D.
(1999)
Protein Sci.
8,
435-438[Abstract]
11.
Ford, M. G.,
Pearse, B. M.,
Higgins, M. K.,
Vallis, Y.,
Owen, D. J.,
Gibson, A.,
Hopkins, C. R.,
Evans, P. R.,
and McMahon, H. T.
(2001)
Science
291,
1051-1055 12.
Itoh, T.,
Koshiba, S.,
Kigawa, T.,
Kikuchi, A.,
Yokoyama, S.,
and Takenawa, T.
(2001)
Science
291,
1047-1051 13.
De Camilli, P.,
Chen, H.,
Hyman, J.,
Panepucci, E.,
Bateman, A.,
and Brunger, A. T.
(2002)
FEBS Lett.
513,
11-18[CrossRef][Medline]
[Order article via Infotrieve]
14.
Bennett, E. M.,
Chen, C. Y.,
Engqvist-Goldstein, A. E.,
Drubin, D.,
and Brodsky, F. M.
(2001)
Traffic
2,
851-858[CrossRef][Medline]
[Order article via Infotrieve]
15.
Metzler, M.,
Legendre-Guillemin, V.,
Gan, L.,
Chopra, V.,
Kwok, A.,
McPherson, P. S.,
and Hayden, M. R.
(2001)
J. Biol. Chem.
276,
39271-39276 16.
Waelter, S.,
Scherzinger, E.,
Hasenbank, R.,
Nordhoff, E.,
Lurz, R.,
Goehler, H.,
Gauss, C.,
Sathasivam, K.,
Bates, G. P.,
Lehrach, H.,
and Wanker, E. E.
(2001)
Hum. Mol. Genet.
10,
1807-1817 17.
Mishra, S. K.,
Agostinelli, N. R.,
Brett, T. J.,
Mizukami, I.,
Ross, T. S.,
and Traub, L. M.
(2001)
J. Biol. Chem.
276,
46230-46236 18.
Maycox, P. R.,
Link, E.,
Reetz, A.,
Morris, S. A.,
and Jahn, R.
(1992)
J. Cell Biol.
118,
1379-1388 19.
Engqvist-Goldstein, A. E.,
Warren, R. A.,
Kessels, M. M.,
Keen, J. H.,
Heuser, J.,
and Drubin, D. G.
(2001)
J. Cell Biol.
154,
1209-1223 20.
Yang, W., Lo, C. G.,
Dispenza, T.,
and Cerione, R. A.
(2001)
J. Biol. Chem.
276,
17468-17473 21.
Teo, M.,
Tan, L.,
Lim, L.,
and Manser, E.
(2001)
J. Biol. Chem.
276,
18392-18398 22.
Morgan, J. R.,
Zhao, X.,
Womack, M.,
Prasad, K.,
Augustine, G. J.,
and Lafer, E. M.
(1999)
J. Neurosci.
19,
10201-10212 23.
Drake, M. T.,
and Traub, L. M.
(2001)
J. Biol. Chem.
276,
28700-28709 24.
Schmid, S. L.
(1997)
Annu. Rev. Biochem.
66,
511-548[CrossRef][Medline]
[Order article via Infotrieve]
25.
McPherson, P. S.
(1999)
Cell. Signal.
11,
229-238[CrossRef][Medline]
[Order article via Infotrieve]
26.
Marsh, M.,
and McMahon, H. T.
(1999)
Science
285,
215-220 27.
Slepnev, V. I.,
and De Camilli, P.
(2000)
Nat. Rev. Neurosci.
1,
161-172[Medline]
[Order article via Infotrieve]
28.
Keen, J. H.,
Willingham, M. C.,
and Pastan, I. H.
(1979)
Cell
16,
303-312[CrossRef][Medline]
[Order article via Infotrieve]
29.
Slepnev, V. I.,
Ochoa, G. C.,
Butler, M. H.,
and De Camilli, P.
(2000)
J. Biol. Chem.
275,
17583-17589 30.
Drake, M. T.,
Downs, M. A.,
and Traub, L. M.
(2000)
J. Biol. Chem.
275,
6479-6489 31.
Laporte, S. A.,
Oakley, R. H.,
Zhang, J.,
Holt, J. A.,
Ferguson, S. S.,
Caron, M. G.,
and Barak, L. S.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
3712-3717 32.
Owen, D. J.,
Vallis, Y.,
Noble, M. E.,
Hunter, J. B.,
Dafforn, T. R.,
Evans, P. R.,
and McMahon, H. T.
(1999)
Cell
97,
805-815[CrossRef][Medline]
[Order article via Infotrieve]
33.
Traub, L. M.,
Downs, M. A.,
Westrich, J. L.,
and Fremont, D. H.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
8907-8912 34.
Ramjaun, A. R.,
Micheva, K. D.,
Bouchelet, I.,
and McPherson, P. S.
(1997)
J. Biol. Chem.
272,
16700-16706 35.
Ramjaun, A. R.,
and McPherson, P. S.
(1998)
J. Neurochem.
70,
2369-2376[Medline]
[Order article via Infotrieve]
36.
Ahle, S.,
Mann, A.,
Eichelsbacher, U.,
and Ungewickell, E.
(1988)
EMBO J.
7,
919-929[Medline]
[Order article via Infotrieve]
37.
Gaidarov, I.,
Santini, F.,
Warren, R. A.,
and Keen, J. H.
(1999)
Nat. Cell. Biol.
1,
1-7[CrossRef][Medline]
[Order article via Infotrieve]
38.
Qualmann, B.,
Kessels, M. M.,
and Kelly, R. B.
(2000)
J. Cell Biol.
150,
F111-116 39.
Micheva, K. D.,
Holz, R. W.,
and Smith, S. J.
(2001)
J. Cell Biol.
154,
355-368 40.
Kelly, M. A.,
and McCann, R. O.
(2001)
Mol. Biol. Cell
12,
156a
41.
Ybe, J. A.,
Greene, B.,
Liu, S. H.,
Pley, U.,
Parham, P.,
and Brodsky, F. M.
(1998)
EMBO J.
17,
1297-1303[CrossRef][Medline]
[Order article via Infotrieve]
42.
Wilde, A.,
Beattie, E. C.,
Lem, L.,
Riethof, D. A.,
Liu, S. H.,
Mobley, W. C.,
Soriano, P.,
and Brodsky, F. M.
(1999)
Cell
96,
677-687[CrossRef][Medline]
[Order article via Infotrieve]
43.
Faber, P. W.,
Barnes, G. T.,
Srinidhi, J.,
Chen, J.,
Gusella, J. F.,
and MacDonald, M. E.
(1998)
Hum. Mol. Genet.
7,
1463-1474 44.
Sittler, A.,
Walter, S.,
Wedemeyer, N.,
Hasenbank, R.,
Scherzinger, E.,
Eickhoff, H.,
Bates, G. P.,
Lehrach, H.,
and Wanker, E. E.
(1998)
Mol. Cell
2,
427-436[CrossRef][Medline]
[Order article via Infotrieve]
45.
DiFiglia, M.,
Sapp, E.,
Chase, K.,
Schwarz, C.,
Meloni, A.,
Young, C.,
Martin, E.,
Vonsattel, J. P.,
Carraway, R.,
and Reeves, S. A.
(1995)
Neuron
14,
1075-1081[CrossRef][Medline]
[Order article via Infotrieve]
46.
Tukamoto, T.,
Nukina, N.,
Ide, K.,
and Kanazawa, I.
(1997)
Brain Res. Mol. Brain Res.
51,
8-14[Medline]
[Order article via Infotrieve]
47.
Velier, J.,
Kim, M.,
Schwarz, C.,
Kim, T. W.,
Sapp, E.,
Chase, K.,
Aronin, N.,
and DiFiglia, M.
(1998)
Exp. Neurol.
152,
34-40[CrossRef][Medline]
[Order article via Infotrieve]
48.
Kegel, K. B.,
Kim, M.,
Sapp, E.,
McIntyre, C.,
Castano, J. G.,
Aronin, N.,
and DiFiglia, M.
(2000)
J. Neurosci.
20,
7268-7278
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
J. D. Wilbur, C.-Y. Chen, V. Manalo, P. K. Hwang, R. J. Fletterick, and F. M. Brodsky Actin Binding by Hip1 (Huntingtin-interacting Protein 1) and Hip1R (Hip1-related Protein) Is Regulated by Clathrin Light Chain J. Biol. Chem., November 21, 2008; 283(47): 32870 - 32879. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Kasprowicz, S. Kuenen, K. Miskiewicz, R. L.P. Habets, L. Smitz, and P. Verstreken Inactivation of clathrin heavy chain inhibits synaptic recycling but allows bulk membrane uptake J. Cell Biol., September 8, 2008; 182(5): 1007 - 1016. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Poupon, M. Girard, V. Legendre-Guillemin, S. Thomas, L. Bourbonniere, J. Philie, N. A. Bright, and P. S. McPherson Clathrin light chains function in mannose phosphate receptor trafficking via regulation of actin assembly PNAS, January 8, 2008; 105(1): 168 - 173. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. V. Bradley, T. S. Hyun, K. I. Oravecz-Wilson, L. Li, E. I. Waldorff, A. N. Ermilov, S. A. Goldstein, C. X. Zhang, D. G. Drubin, K. Varela, et al. Degenerative phenotypes caused by the combined deficiency of murine HIP1 and HIP1r are rescued by human HIP1 Hum. Mol. Genet., June 1, 2007; 16(11): 1279 - 1292. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Metzler, L. Gan, T. Pan Wong, L. Liu, J. Helm, L. Liu, J. Georgiou, Y. Wang, N. Bissada, K. Cheng, et al. NMDA Receptor Function and NMDA Receptor-Dependent Phosphorylation of Huntingtin Is Altered by the Endocytic Protein HIP1 J. Neurosci., February 28, 2007; 27(9): 2298 - 2308. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. M. Newpher, F.-Z. Idrissi, M. I. Geli, and S. K. Lemmon Novel Function of Clathrin Light Chain in Promoting Endocytic Vesicle Formation Mol. Biol. Cell, October 1, 2006; 17(10): 4343 - 4352. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Hinrichsen, A. Meyerholz, S. Groos, and E. J. Ungewickell Bending a membrane: How clathrin affects budding PNAS, June 6, 2006; 103(23): 8715 - 8720. [Abstract] [Full Text] [PDF] |
||||
|
|